# Pamish to supply mPEG-20k to UCB for Cimzia production

Pamish has signed a 6-year supply contract with Belgian pharmaceutical company UCB to provide mPEG-20k, a raw material for UCB's autoimmune disease drug Cimzia. The contract is effective from January 23, 2017, with automatic annual renewals thereafter.

- Type: Contract
- Announced: 2017-01-23
- Status: announced
- Products: mPEG-20k (Methoxy-Polyethylene glycol-20k)
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Pamish](https://endata.com/companies/21624.md)
- [UCB](https://endata.com/companies/21619.md) (customer)

## Sources

- [etoday.co.kr](https://www.etoday.co.kr/news/view/1445538), 2017-01-23: "이번 계약은 UCB사의 자가면역질환 치료제 ‘심지아(Cimzia)’ 생산에 필요한 mPEG-20k를 공급하기 위한 것이다."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.